Integrated cloning and expression platform that combines AI-driven protein variant design with high-efficiency DE3 competent cells and 384-well automation. The workflow accelerates discovery of novel recombinant proteins by enabling thousands of AI-designed sequences to be cloned, expressed, and quality-checked in parallel. Applications include agricultural biotechnology, drug discovery, and industrial enzyme engineering.
Intact Genomics offers an integrated protein engineering platform that pairs AI-driven design of recombinant protein variants with high-throughput cloning and expression in optimized E. coli DE3 lines. The platform combines AI-based sequence generation, the company’s ALL-in-ONE competent cell technology, and an in-house selected set of DE3 strains processed on a 384-well automation platform.
The core value is speed and scale. Traditional workflows often require separate cloning and expression steps and are difficult to parallelize across large variant libraries. By combining AI design with automation and high-efficiency cells, the platform enables researchers to explore broader protein sequence space—including thousands of variants around binding pockets or catalytic regions—and move from sequence to expressed protein more quickly.
Potential applications include agricultural biotechnology, drug discovery, enzyme engineering, and other areas that depend on identifying functional protein variants.
Key features:
The platform is designed to integrate with AI protein design workflows and can be adapted to different target classes depending on project goals.
The individual components—high-efficiency DE3 competent cells, ALL-in-ONE cloning/expression technology, and 384-well automation—are developed and used in molecular biology research settings. The fully integrated AI-to-expression pipeline is at an early validation stage. A proposed feasibility study would validate the workflow by selecting a specific binding pocket or catalytic region, generating candidate sequences, expressing and quality-checking proteins, and performing activity assays to identify five to ten novel structures with improved target activity.
Because this stage depends on the target protein class and assay conditions, the main current limitation is that full end-to-end validation has not yet been completed. Successful feasibility testing would advance the platform toward use in early-stage protein discovery programs.
Intact Genomics is an ISO 13485:2016 certified biotechnology company that specializes in the development and manufacture of high-performance molecular biology reagents and genomic services. Founded in 2013 and based in St. Louis, Missouri, the company leverages proprietary technologies, including Fungal Artificial Chromosomes (FAC) and advanced large DNA fragment cloning, to provide solutions for isothermal DNA/RNA amplification, gene editing, and molecular cloning. Their product portfolio, which includes over 100 items such as high-efficiency competent cells, enzymes, and RPA optimization tools, is designed to support high-quality, reproducible research across diverse fields including human health, agriculture, and environmental science.
The company serves a global customer base across academia and industry, enabling researchers to address complex challenges in genomic structure, function, and natural product discovery. By offering both off-the-shelf molecular biology products and custom services—such as library construction, protein expression, and OEM manufacturing—Intact Genomics provides scalable support for diagnostic development and drug discovery efforts. Their commitment to reliability and innovation has established them as a key resource for laboratories seeking specialized tools for streamlined cloning and rapid isothermal testing methods.